To include your compound in the COVID-19 Resource Center, submit it here.

Hua’s institutional advantage

How diabetes company Hua navigated volatile Hong Kong market to price IPO

The same market forces that drove Hua Medicine Ltd. to reduce the size of its Hong Kong IPO tempered participation by retail investors, which could help keep the Shanghai diabetes company’s share price steady amidst a more volatile market.

Hua shares ended their first day of trading Friday unchanged at HK$8.28. The company raised HK$867 million ($110.5 million) in its offering through the sale of 104.8 million shares at HK$8.28, valuing Hua at HK$8.7

Read the full 731 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers